Ketorolac Ophthalmic (Acular)

Ketorolac ophthalmic, commonly known by the brand name Acular, is a potent non-steroidal anti-inflammatory drug formulated for topical application to the eye, providing effective management of ocular inflammation and pain in horses. This medication belongs to the pyrrolizine carboxylic acid derivative class of NSAIDs and demonstrates particularly strong analgesic properties in addition to its anti-inflammatory effects, making it especially valuable when ocular pain is a prominent component of the clinical presentation. Ketorolac ophthalmic has become an established tool in equine ophthalmology for managing various inflammatory conditions while avoiding the risks associated with corticosteroid therapy.

The mechanism of action of ketorolac involves inhibition of cyclooxygenase enzymes, thereby blocking the biosynthesis of prostaglandins that serve as key mediators of inflammation and pain within ocular tissues. Prostaglandins contribute significantly to the inflammatory response by causing vasodilation, increasing vascular permeability, and sensitizing nociceptors to painful stimuli. By reducing prostaglandin production at the site of application, ketorolac effectively diminishes these inflammatory and pain responses. The particularly strong analgesic effect of ketorolac among ophthalmic NSAIDs makes it a preferred choice when pain control is a primary treatment objective.

Ketorolac ophthalmic is supplied as a sterile aqueous solution containing ketorolac tromethamine at concentrations of 0.4 or 0.5 percent, depending on the specific product formulation. The solution is applied as drops directly into the conjunctival sac, where it absorbs into ocular tissues to exert local anti-inflammatory and analgesic effects. Various formulations may differ in their preservative content and other inactive ingredients. Dosing frequency is determined by the treating veterinarian based on the specific condition and clinical response, typically ranging from two to four times daily for most applications.

The safety profile of ketorolac ophthalmic provides significant advantages over corticosteroid preparations in specific clinical situations. As a non-steroidal agent, ketorolac does not cause the degree of local immunosuppression associated with corticosteroids, making it safer when infection risk is present. Critically, ketorolac ophthalmic can be administered to horses with corneal ulcers to manage inflammation and pain while the epithelial defect heals, a situation where corticosteroids are absolutely contraindicated. However, potential adverse effects including possible delays in corneal epithelial healing warrant appropriate veterinary oversight throughout treatment.

One of the most valuable applications of ketorolac ophthalmic in equine medicine is the management of pain and inflammation associated with corneal ulceration. Corneal ulcers represent among the most common and potentially serious eye emergencies in horses, causing significant discomfort and carrying risk of vision-threatening complications. While the ulcer itself requires antimicrobial therapy and supportive care, the accompanying inflammation and pain significantly affect patient welfare. Ketorolac's strong analgesic properties make it particularly effective for reducing the obvious discomfort horses experience with corneal injuries, while its anti-inflammatory action helps control the inflammatory component without the healing inhibition and infection risk associated with corticosteroids.

Post-surgical pain and inflammation management represents another important indication for ketorolac ophthalmic in horses. Following ocular procedures including eyelid surgery, conjunctival procedures, corneal surgery, or intraocular operations, patients experience expected post-operative inflammation and discomfort. Ketorolac effectively addresses both components, reducing inflammation while providing meaningful pain relief that supports patient comfort during recovery. The medication may be used alone or in combination with other agents depending on the procedure performed and the veterinarian's assessment of clinical needs.

Ketorolac ophthalmic is employed in managing equine recurrent uveitis and other forms of anterior uveitis, either as adjunct therapy alongside corticosteroids or as an alternative when steroid exposure should be minimized. The painful nature of uveitis makes ketorolac's strong analgesic properties particularly beneficial. While corticosteroids provide more potent anti-inflammatory effects, ketorolac offers meaningful inflammation control with excellent pain management and reduced concerns about immunosuppression. This makes it valuable during the tapering phase of corticosteroid therapy or for maintenance between acute flares in horses with chronic recurrent disease.

Seasonal allergic conjunctivitis affecting horses may respond to ketorolac ophthalmic therapy. The itching, redness, and discomfort associated with allergic eye disease are mediated in part by prostaglandins, making NSAID therapy a rational approach. Ketorolac can reduce the inflammatory component of allergic responses while providing relief from associated discomfort. For horses with recurrent seasonal allergies, ketorolac offers an alternative to corticosteroids for managing symptoms, particularly when long-term or repeated treatment courses are anticipated.

Traumatic ocular injuries without corneal epithelial defects represent additional situations where ketorolac ophthalmic provides therapeutic benefit. Blunt trauma causing periorbital inflammation, conjunctival injury, or mild anterior segment inflammation can be effectively managed with topical NSAID therapy. The analgesic effects help maintain patient comfort while the anti-inflammatory action reduces swelling and promotes recovery. When corneal involvement is suspected, veterinary examination including fluorescein staining should confirm epithelial integrity before initiating any treatment.

The dosing protocol for ketorolac ophthalmic in horses is established by the treating veterinarian based on the specific clinical indication, condition severity, and individual patient factors. Unlike systemic medications where body weight determines dose, ophthalmic preparations are dosed by application frequency and number of drops rather than total drug amount. Standard formulations contain ketorolac tromethamine at 0.4 or 0.5 percent concentration, and this concentration is used across all indications with frequency adjustments to meet varying clinical needs. Horse owners must follow the prescribed regimen precisely and avoid modifying the treatment schedule without veterinary guidance.

For managing inflammation and pain associated with corneal ulceration, ketorolac ophthalmic is typically prescribed two to four times daily depending on the severity of discomfort and inflammation observed. Treatment continues alongside appropriate antimicrobial therapy and other supportive care until the ulcer has healed and inflammation has resolved. The veterinarian monitors healing progress through regular examinations including fluorescein staining and adjusts the treatment protocol based on clinical response. More frequent dosing may be indicated initially for severe pain, with reduction as the condition improves.

Post-surgical protocols vary based on the procedure performed and expected inflammation level. Treatment typically begins immediately after surgery and continues for one to several weeks depending on the intervention and healing response. A common approach involves four times daily application for the first several days, then gradual reduction in frequency as inflammation resolves. The veterinarian monitors recovery through scheduled examinations and adjusts the treatment course accordingly. Combination with other medications including corticosteroids may be appropriate for certain procedures.

For uveitis management and other inflammatory conditions, ketorolac dosing frequency depends on whether the medication serves as primary therapy, adjunct therapy, or maintenance treatment. When used alongside corticosteroids during acute flares, both medications follow their prescribed schedules with appropriate spacing between different preparations. As maintenance therapy, twice to four times daily application is common. The strong analgesic properties of ketorolac make it particularly valuable during painful episodes.

Proper administration technique ensures effective drug delivery and maintains medication sterility. The handler should approach the horse calmly and gently clean any discharge from around the eye before application. The lower eyelid is carefully retracted to expose the conjunctival sac, and one to two drops are applied directly into this pocket as prescribed. The dropper tip must never contact the eye or surrounding tissues to prevent contamination. The horse may blink or show mild transient discomfort after application, which is normal. When multiple eye medications are prescribed, a minimum of five minutes should separate applications of different preparations.

Missed doses should be given when remembered unless the next scheduled dose is imminent, in which case the missed dose is skipped and the regular schedule resumed. Doubling doses to compensate for missed applications is not recommended. If multiple consecutive doses are missed, contacting the veterinarian for guidance on resuming treatment is advisable. Consistent, regular administration optimizes both anti-inflammatory and analgesic effects throughout the treatment course.

Ketorolac ophthalmic is generally well tolerated by horses when administered as directed under appropriate veterinary supervision. Most effects observed during treatment are mild, localized, and self-limiting, representing normal responses to medication rather than adverse reactions requiring intervention. However, awareness of potential side effects enables horse owners and caretakers to recognize complications early and seek prompt veterinary attention when needed, optimizing outcomes for treated patients.

Mild transient discomfort immediately following application is the most commonly observed effect of ketorolac ophthalmic. This typically manifests as brief stinging or burning sensation, increased blinking, mild head movement, or temporary tearing that resolves within one to two minutes. These responses represent normal sensory reactions to foreign substances in the eye and do not indicate medication intolerance. The discomfort often diminishes with repeated applications as the horse becomes accustomed to the treatment routine. Severe or prolonged discomfort warrants veterinary evaluation.

Corneal effects represent the most clinically significant potential adverse effects associated with ketorolac and other topical ophthalmic NSAIDs. While a major advantage of these medications over corticosteroids is the ability to use them with corneal ulcers present, evidence suggests that NSAIDs may slow corneal epithelial healing to some degree. This effect is generally mild and clinically acceptable when balanced against the benefits of pain relief and inflammation control, but it emphasizes the importance of regular veterinary monitoring to track healing progress during treatment of corneal injuries.

Rare but serious corneal complications including stromal thinning or melting have been reported with prolonged topical ophthalmic NSAID use, particularly in predisposed patients or compromised corneas. These complications, while uncommon, can be severe and are typically associated with extended treatment courses or underlying corneal disease. Any worsening of corneal appearance, new or increased cloudiness, progressive pain despite treatment, or other signs suggesting corneal deterioration require immediate veterinary evaluation and likely discontinuation of the medication.

Systemic side effects from ketorolac ophthalmic are minimal due to limited absorption from topical ocular administration. The amount of drug reaching systemic circulation through conjunctival absorption and nasolacrimal drainage is insufficient to cause the gastrointestinal ulceration, renal effects, or coagulation changes associated with systemic NSAID administration in horses. Horses receiving concurrent systemic NSAID therapy should have their total NSAID exposure considered by the veterinarian, though clinically significant additive systemic effects from topical ophthalmic doses are not typically expected.

Known hypersensitivity to ketorolac, other NSAIDs, or any component of the ophthalmic formulation constitutes an absolute contraindication to use. Horses with documented allergic or adverse reactions to ketorolac or related NSAID medications should not receive this product. Cross-sensitivity among different NSAIDs may occur in susceptible individuals, so horses with known adverse reactions to any NSAID warrant particular caution if an alternative ophthalmic NSAID is being considered. Signs of hypersensitivity may include worsening rather than improving signs, severe irritation, or unexpected adverse responses that do not resolve with continued treatment.

While ketorolac ophthalmic can generally be used in the presence of simple corneal ulceration, representing a significant advantage over corticosteroids, certain severe or complicated corneal conditions warrant caution or avoidance. Deep stromal ulcers approaching Descemet's membrane, descemetoceles, actively melting corneas, or corneas showing progressive deterioration present increased risk for complications with anti-inflammatory therapy. The decision to use ketorolac in complicated corneal disease requires careful veterinary assessment of potential benefits versus risks for each individual case. When corneal integrity is severely compromised, immediate surgical intervention and intensive antimicrobial therapy take priority over anti-inflammatory treatment.

Horses with known bleeding disorders or those receiving anticoagulant therapy require careful consideration before ketorolac ophthalmic use. NSAIDs inhibit platelet function through cyclooxygenase inhibition, which can affect coagulation. While systemic effects from topical ophthalmic administration are minimal, horses with significant coagulopathies or those on systemic anticoagulant medications should be monitored carefully for any unusual bleeding. Any bleeding or bruising around the treated eye during therapy should prompt veterinary evaluation.

Concurrent use of multiple topical ophthalmic NSAID preparations is not recommended, as this provides no additional therapeutic benefit while potentially increasing adverse effect risk. While combining a topical NSAID with a topical corticosteroid may be appropriate in specific situations under veterinary supervision, simultaneous use of different NSAID eye drops serves no useful purpose. Pregnant mares warrant consideration before any NSAID administration due to the known effects of this drug class on pregnancy maintenance and fetal development, though systemic absorption from ophthalmic administration is limited. The treating veterinarian weighs potential risks against benefits when prescribing ketorolac ophthalmic to pregnant mares with significant ocular disease.

When multiple ophthalmic medications are prescribed concurrently, appropriate spacing between applications ensures adequate absorption and therapeutic effect of each agent. Ketorolac ophthalmic should be administered at least five to ten minutes apart from other eye drops or ointments. This interval allows sufficient time for the first medication to absorb into ocular tissues before the next is applied, preventing dilution or washout effects. When both solutions and ointments are prescribed, solutions should generally be administered first, as ointment formulations create a barrier that can impair subsequent drug absorption.

Combination therapy using ketorolac ophthalmic alongside topical corticosteroids may be employed in specific clinical situations where enhanced anti-inflammatory effects are desired or where reducing individual drug exposure is beneficial. This approach requires veterinary supervision and appropriate monitoring. For example, following certain surgical procedures or during management of severe uveitis, the combination may provide improved inflammation and pain control compared to either agent alone. The veterinarian determines appropriate dosing schedules and monitors for potential adverse effects from the combined therapy.

Systemic NSAID administration concurrent with topical ophthalmic ketorolac presents consideration for total body NSAID exposure. While absorption from ophthalmic administration is minimal, horses receiving systemic phenylbutazone, flunixin meglumine, firocoxib, or other NSAIDs already have cyclooxygenase inhibition throughout the body. The additional ocular NSAID is unlikely to significantly increase systemic adverse effect risk, but veterinarians consider comprehensive drug exposure when designing treatment protocols. The critical systemic NSAID warning regarding never combining multiple systemic NSAIDs in horses remains paramount, while topical ophthalmic preparations present minimal systemic interaction risk.

Topical antimicrobial agents including antibiotics and antifungals are frequently prescribed alongside ketorolac when treating infected or potentially infected corneal conditions or following surgical procedures. These combinations are therapeutically appropriate with proper administration spacing. The anti-inflammatory and analgesic effects of ketorolac complement the antimicrobial action by controlling inflammation and improving patient comfort while the infection is being treated. Competition horses receiving ketorolac ophthalmic should be aware that this medication, like all NSAIDs, is subject to competition regulations. Consultation with veterinarians familiar with applicable rules and potentially pre-competition testing is advisable for horses in active competition programs.

Regular veterinary monitoring during ketorolac ophthalmic treatment ensures appropriate therapeutic response and enables early identification of any complications. The frequency and nature of monitoring depend on the condition being treated and its severity. Horses with corneal ulcers typically require frequent rechecks, often daily or every other day initially, with fluorescein staining to track healing progress. Post-surgical patients need monitoring of healing and inflammation resolution. Less acute inflammatory conditions may be followed at longer intervals as determined by the veterinarian. Owners should report any changes suggesting worsening between scheduled visits.

Special patient populations warrant additional consideration when prescribing ketorolac ophthalmic. Foals may respond differently to medications compared to adult horses due to developmental factors and immature organ function, and treatment protocols should be adjusted accordingly under veterinary guidance. Geriatric horses frequently have concurrent health conditions affecting overall treatment decisions. Horses with systemic illness, particularly conditions affecting coagulation, warrant careful evaluation. Pregnant mares represent a population where NSAID exposure raises theoretical concerns regarding effects on pregnancy, though minimal systemic absorption from ophthalmic administration limits this risk.

Competition and performance horses face regulatory considerations with ketorolac ophthalmic use. Regulatory bodies including the Federation Equestre Internationale, United States Equestrian Federation, and various racing commissions maintain prohibited substance lists that include NSAIDs. While detection following topical ophthalmic administration is substantially lower than systemic routes, ketorolac may be detectable in samples from treated horses depending on formulation, frequency, and duration of treatment. Horse owners and trainers must consider competition schedules when planning treatment, and consultation regarding appropriate withdrawal times is essential. Current rules should always be verified as regulations are subject to change.

Administration precautions protect both handler safety and medication integrity. The dropper tip must never contact the eye, eyelids, or surrounding tissues to maintain sterility and prevent potential injury. Hands should be washed before and after medication handling. Proper restraint ensures accurate medication placement while keeping handlers safe from sudden head movements. Some horses require gradual desensitization to comfortably accept ophthalmic medication administration, and patient training during initial treatments improves long-term compliance. Establishing a consistent, calm routine reduces stress for both horse and handler.

Long-term use of ketorolac ophthalmic warrants periodic reassessment of treatment necessity and monitoring for cumulative effects. While topical ophthalmic NSAIDs present fewer concerns with extended use than corticosteroids, chronic administration still requires veterinary oversight. Potential corneal effects from prolonged NSAID exposure should be evaluated through regular examinations. The lowest effective treatment frequency should be identified when long-term therapy is necessary. For conditions requiring indefinite anti-inflammatory management, alternative therapeutic approaches may be considered to reduce total drug exposure over time.

Ketorolac ophthalmic solution should be stored at controlled room temperature between fifteen and twenty-five degrees Celsius (fifty-nine to seventy-seven degrees Fahrenheit), protected from light and excessive heat. The medication should not be frozen, as freezing can damage the formulation and compromise effectiveness or safety. Barn and stable environments often experience temperature fluctuations that could affect medication stability, so storing ophthalmic preparations in a climate-controlled location and transporting them to the barn for each administration may be necessary. The bottle should remain tightly capped when not in use to prevent contamination and maintain proper concentration.

Handling practices focus on maintaining sterility and preventing contamination of the medication throughout the treatment course. The dropper tip should never contact any surface including the eye, eyelids, surrounding tissues, fingers, or any other objects that could introduce microorganisms into the bottle. Before administration, hands should be washed thoroughly with soap and water. The area around the horse's eye should be gently cleaned of discharge or debris before applying medication. Immediately after dispensing the prescribed drops, the cap should be replaced securely. If the solution appears cloudy, discolored, or contains visible particles, it should not be used, and the veterinarian should be consulted regarding replacement.

Expiration dates printed on ketorolac ophthalmic containers must be strictly observed, as degraded medication may lose effectiveness and could potentially cause adverse effects. Beyond the manufacturer's printed expiration date, most multi-dose ophthalmic solutions should be discarded twenty-eight days after opening, regardless of remaining volume. Recording the date opened on the bottle helps track this discard timeline. Expired or outdated medications should be disposed of properly rather than saved for potential future use. Pharmacy take-back programs or disposal as directed by local guidelines represent preferred disposal methods. All medications should be stored out of reach of children and animals to prevent accidental exposure or ingestion.

Appaloosa horses warrant particular attention regarding ketorolac ophthalmic use due to their markedly increased prevalence of equine recurrent uveitis. This painful, recurring inflammatory condition of the eye makes Appaloosas frequent candidates for anti-inflammatory therapy. Ketorolac's strong analgesic properties make it particularly valuable for managing the significant pain associated with uveitis episodes. While corticosteroids remain primary therapy during acute flares due to their superior anti-inflammatory potency, ketorolac may serve as adjunct therapy, maintenance treatment, or an option when minimizing corticosteroid exposure is desirable. Appaloosa owners should remain vigilant for uveitis signs including squinting, tearing, cloudiness, and sensitivity to light.

Draft horses including Belgians, Percherons, Clydesdales, and Shires present practical considerations for ophthalmic medication administration related to their substantial size. The larger head and eyes of these breeds may facilitate accurate medication placement, though handler height relative to the horse's eye level can present challenges. Draft breeds are often characterized by calm, cooperative temperaments that simplify medication routines. Drug responses to topical ophthalmic medications appear similar across horse sizes since dosing depends on application frequency rather than body weight, so no specific adjustments are typically required for draft breeds.

Ponies and miniature horses require careful, precise medication application due to their smaller eye size. Accurate placement of drops into the conjunctival sac is important for effective drug delivery with minimal waste. Some miniature horses may have proportionally larger eyes relative to head size, which can facilitate administration. These smaller equines may exhibit more reactive temperaments regarding handling around the head, necessitating patience and appropriate restraint techniques. Establishing consistent, calm administration routines from the beginning of treatment improves long-term compliance and reduces stress.

Thoroughbreds, Warmbloods, Quarter Horses, Arabians, and other breeds do not demonstrate documented breed-specific variations in response to ketorolac ophthalmic. Standard dosing protocols apply across breeds, with individual patient variation being more clinically significant than breed factors. However, breeds with increased prevalence of specific ocular conditions may require more frequent or prolonged anti-inflammatory therapy. Performance horses of all breeds must carefully consider regulatory implications of medication use when competing under the rules of various governing bodies, as NSAIDs are commonly regulated substances in competition.

Within the topical ophthalmic NSAID class, several alternatives to ketorolac offer similar anti-inflammatory effects through cyclooxygenase inhibition. Diclofenac ophthalmic (Voltaren) provides comparable anti-inflammatory action and is commonly used for managing ocular inflammation in horses. Flurbiprofen ophthalmic (Ocufen) represents another established option with particular utility for preventing intraoperative miosis during ocular surgery. These medications share the general characteristics of the NSAID class, including the critical advantage of being usable in the presence of corneal ulceration and the potential for effects on corneal epithelial healing with extended use. Ketorolac may be preferred when particularly strong analgesia is desired due to its notable pain-relieving properties among ophthalmic NSAIDs.

Corticosteroid ophthalmic preparations provide substantially more potent anti-inflammatory effects than topical NSAIDs and remain primary therapy for many inflammatory eye conditions in horses. Dexamethasone ophthalmic and prednisolone acetate ophthalmic are frequently used corticosteroid options offering powerful suppression of ocular inflammation through mechanisms distinct from NSAIDs. However, corticosteroids carry important risks including local immunosuppression that can allow infection progression, absolute contraindication when corneal epithelial defects exist, and potential for elevated intraocular pressure with prolonged use. The choice between NSAIDs and corticosteroids depends on clinical circumstances, corneal integrity, infection risk assessment, and individual patient factors.

For horses requiring long-term management of chronic immune-mediated ocular conditions such as equine recurrent uveitis, cyclosporine ophthalmic preparations offer an immunomodulatory approach distinct from both NSAIDs and corticosteroids. Cyclosporine inhibits T-cell activation and may provide effective maintenance therapy while reducing cumulative exposure to traditional anti-inflammatory drugs. This medication may be used in conjunction with ketorolac or corticosteroids as part of comprehensive management protocols. Atropine ophthalmic is commonly used alongside anti-inflammatory medications to maintain pupil dilation and provide comfort in horses with painful conditions like uveitis. All medication selections and treatment adjustments should be made by the treating veterinarian based on thorough examination and ongoing clinical assessment.